Clinical Trials Sponsored by Istituto Oncologico Veneto IRCCS

Total 71 results

Istituto Oncologico Veneto IRCCS

Recruiting

ImmunoNutrition and Colorectal Adenocarcinoma Surgery - INCAS Study (INCAS)

Colorectal Adenocarcinoma

Italy
Istituto Oncologico Veneto IRCCS

Recruiting

Pure Florid and Pleomorphic Lobular Carcinoma in Situ of the Breast: Towards an Increasingly Uniform Management

Pleomorphic Lobular Breast Carcinoma in Situ | Breast Florid Lobular Carcinoma in Situ

Italy
Istituto Oncologico Veneto IRCCS

Recruiting

OLIGOS: Impact of Treatment on Primary Tumour in Patients With Newly Diagnosed Oligometastatic Neoplasia of the Prostate (OLIGOS)

Oligometastatic Prostate Carcinoma

Italy
Istituto Oncologico Veneto IRCCS

Active, not recruiting

Cabozantinib in the Elderly With Metastatic Renal Cell Carcinoma (ZEBRA)

Renal Cell Carcinoma

Italy
Istituto Oncologico Veneto IRCCS

Completed

Epidemiological Features and Clinical Course of COVID -19 Infection in Cancer Patients: The Rovid Study

Solid Tumor, Adult

Italy
Istituto Oncologico Veneto IRCCS

Completed

Regorafenib in Patients With Relapsed Glioblastoma. IOV-GB-1-2020 REGOMA-OSS

Glioblastoma Multiforme

Italy
Istituto Oncologico Veneto IRCCS

Active, not recruiting

First-line Combination of Capecitabine and Oxaliplatin Plus Bevacizumab in Elderly Patients With Metastatic Colorectal Cancer (COBRA)

Elderly Metastatic Colorectal Cancer Patients

Italy
Istituto Oncologico Veneto IRCCS

Completed

CAlorie and Protein REstriction PROgram in Barrett's Esophagus Patients (CARE-PRO). (CARE-PRO)

Overweight and Obesity | Barrett's Esophagus
Istituto Oncologico Veneto IRCCS

Terminated

TIvantinib as Maintenance Treatment in Extended Small-cell Lung Cancer (TIMES) (TIMES)

Carcinoma, Small Cell

Italy
Istituto Oncologico Veneto IRCCS

Active, not recruiting

First Line Osimertinib in the Real World: an Inter-regional Prospective Study (FLOWER)

EGF-R Positive Non-Small Cell Lung Cancer

Italy
Istituto Oncologico Veneto IRCCS

Completed

Videoscopic Ilioinguinal Lymphadenectomy for Melanoma

Melanoma | Secondary Malignant Neoplasm of Lymph Node
Istituto Oncologico Veneto IRCCS

Completed

Psychological Counselling in Diagnostic Screening

Cancer
Istituto Oncologico Veneto IRCCS
Bayer

Not yet recruiting

Regorafenib for Recurrent Grade 2 and 3 Meningioma (MIRAGE Trial) (MIRAGE)

Meningioma, Malignant

Italy
Istituto Oncologico Veneto IRCCS
Regione del Veneto (Italy)

Active, not recruiting

Risk-Based Breast Screening in Young Women (RIBBS)

Breast Neoplasms

Italy
Istituto Oncologico Veneto IRCCS
Bayer S.p.A

Recruiting

Regorafenib With Temozolomide With or Without RT in MGMT-Methylated, IDH Wild-type GBM Patients (REGOMA-2)

Glioblastoma, IDH-wildtype | MGMT-Methylated Glioblastoma

Italy
Istituto Oncologico Veneto IRCCS
Indena S.p.A

Completed

Role of SAMITAL® in the Relief of Chemo-radiation (CT-RT) Induced Oral Mucositis in Head and Neck Cancer Patients (ROSAM)

Oral Mucositis | Head-and-neck Squamous Cell Carcinoma

Italy
Istituto Oncologico Veneto IRCCS
MSD Italia S.r.l.

Not yet recruiting

Induction Chemo+Immunotherapy in Resectable Epithelioid and Biphasic Pleural Mesothelioma (CHIMERA Study) (CHIMERA)

Pleural Mesothelioma

Italy
Istituto Oncologico Veneto IRCCS
Roche Pharma AG

Active, not recruiting

The GOLD Study: G8 in OLDer Patients (GOLD)

Elderly Metastatic Colorectal Cancer Patients

Italy
Istituto Oncologico Veneto IRCCS
BAYER S.p.A. - Italia

Completed

Regorafenib in Relapsed Glioblastoma (REGOMA)

Glioblastoma Multiforme

Italy
Istituto Oncologico Veneto IRCCS
University of Padova

Completed

Neoadjuvant Chemo-endocrine Therapy and Immunotherapy for Pre-menopausal Luminal B Breast Cancer Patients (GIADA)

Breast Cancer

Italy
Istituto Oncologico Veneto IRCCS
Janssen Diagnostics, LLC

Unknown

Circulating Melanoma Cells in Metastatic Patients Treated With Selective BRAF Inhibitors (CMCBRAF)

Metastatic Melanoma

Italy
Istituto Oncologico Veneto IRCCS
University of Padova

Completed

Maintenance Aromatase Inhibitors (AIs)+ Everolimus vs AIs in Hormone Receptor Positive Metastatic Breast Cancer Patients (MAIN-A)

Breast Cancer Metastatic

Italy
Istituto Oncologico Veneto IRCCS
Fondazione Guido Berlucchi

Completed

Totally Implantable Venous Access Devices: Quality of Life and Body Image (BI-PORT)

Neoplasms Undergoing Chemotherapy

Italy
Istituto Oncologico Veneto IRCCS
Fidia Farmaceutici s.p.a.

Not yet recruiting

A Study to Evaluate Efficacy and Safety of Hydeal Cyst® Intravesical Instillations in Patients Treated With Intravesical Chemotherapy or Immunotherapy in Non-muscle Invasive Bladder Cancer (Hydeal Cyst)

Non-muscle Invasive Bladder Cancer

Italy
Azienda Sanitaria Ospedaliera
Istituto Oncologico Veneto IRCCS

Recruiting

LIver TrAnspLantation for Non-resectable Peri-HIlar cholangioCArcinoma (LITALHICA) (LITALHICA)

Perihilar Cholangiocarcinoma

Italy
Azienda Sanitaria Ospedaliera
Istituto Oncologico Veneto IRCCS

Recruiting

LIver Transplantation for Non-Resectable Intrahepatic CholAngiocarcinoma (LIRICA) (LIRICA)

Intrahepatic Cholangiocarcinoma

Italy
Azienda Ospedaliera di Padova
Istituto Oncologico Veneto IRCCS

Recruiting

Resection And Partial Liver Segmental Transplantation With Delayed Total Hepatectomy (RAPID-Padova)

Liver Metastases

Italy
Istituto Oncologico Veneto IRCCS
Ministry of Health, Italy

Recruiting

Low Dose Continuous Cyclophosphamide vs Standard Doxorubicin in Advanced Sarcoma Elderly Patients (METROPHOLYS)

Soft Tissue Sarcoma Adult

Italy
Azienda Ospedaliera di Padova
Istituto Oncologico Veneto IRCCS

Recruiting

Colorectal Metastasis and Liver Transplantation With Organs From Deceased Donors (MELODIC)

Colorectal Adenocarcinoma | Colorectal Liver Metastases | Unresectable Malignant Neoplasm

Italy
Istituto Oncologico Veneto IRCCS
Ministry of Health, Italy

Completed

Individualized Treatment of Patients With Advanced NSCLC: Potential Application for Circulating Tumor Cells (CTC) Molecular and Phenotypical Profiling (2012/52)

Advanced Non Small Cell Lung Cancer

Italy
Istituto Oncologico Veneto IRCCS
University of Padova; Dipartimento di scienze chirurgiche, Oncologiche e Gastroenterologiche

Active, not recruiting

Adjuvant Treatment for High-risk Triple Negative Breast Cancer Patients With the Anti-PD-l1 Antibody Avelumab (A-Brave)

Triple Negative Breast Neoplasms

Italy, United Kingdom
University of Padova
Istituto Oncologico Veneto IRCCS; Fondazione Guido Berlucchi

Terminated

Quality of Life After Esophagectomy for Cancer - Step 1

Quality of Life | Esophageal Cancer | Sleep Disturbance

Italy
University of Padova
Istituto Oncologico Veneto IRCCS; Humanitas Hospital, Italy

Completed

Health and Employment After Gastro Intestinal Surgery - HEAGIS1 (HEAGIS1)

Esophageal Neoplasms | Colonic Neoplasms | Stomach Neoplasm

Italy
University of Padova
Istituto Oncologico Veneto IRCCS; Humanitas Hospital, Italy

Unknown

Health and Employment After Gastro Intestinal Surgery - HEAGIS2 (HEAGIS2)

Esophageal Neoplasms | Colon Neoplasms | Gastric Neoplasm

Italy
Istituto Oncologico Veneto IRCCS
Association for Translational Research in Oncology (AS.T.R.O.)

Completed

Preoperative Study With Trastuzumab, Pertuzumab and Letrozole in Breast Cancer Patients Sensitive to Hormonal Therapy (PER-ELISA)

Endocrine Sensitive HER2+/HR+ Breast Cancer

Italy
Istituto Oncologico Veneto IRCCS
Azienda Ospedaliera di Padova; Azienda ULSS 16 Padova

Completed

Immunophenotyping of Metastases From Colorectal Cancer

Metastatic Colorectal Cancer

Italy
Istituto Oncologico Veneto IRCCS
Azienda Ospedaliera di Padova; Azienda Ospedaliero-Universitaria Careggi, Firenze

Recruiting

An Integrated Radio-immunological Approach (IMMUNO-IMAGING)

Glioma, Malignant

Italy
European Institute of Oncology
Istituto Oncologico Veneto IRCCS; Ente Ospedaliero Ospedali Galliera; Istituto...

Not yet recruiting

Low Dose TamOxifen and LifestylE Changes for bReast cANcer prevenTion (TOLERANT)

Ductal Carcinoma in Situ | RAD51C Gene Mutation | RAD51D Gene Mutation | PALB2 Gene Mutation | Lobular Carcinoma in Situ | ATM Gene Mutation | CDH1 Gene Mutation | CHEK2 Gene Mutation | BRCA Mutation

Italy
Marco G Paggi, MD, PhD
Istituto Oncologico Veneto IRCCS; Regina Elena Cancer Institute; Carlo Besta...

Recruiting

Repurposing Chlorpromazine in the Treatment of Glioblastoma (RACTAC)

Glioblastoma Multiforme | MGMT-Unmethylated Glioblastoma

Italy
Istituto Oncologico Veneto IRCCS
Azienda Ulss 2 Marca Trevigiana; Azienda ULSS 3 Serenissima; Regione Veneto; Azienda... and other collaborators

Completed

Conservative Management of CIN2 Lesions and Biomarkers Evaluation

CIN2

Italy
University of Padova
Fondazione Policlinico Universitario Agostino Gemelli IRCCS; Istituto Oncologico... and other collaborators

Unknown

Rectal Sparing Approach After Preoperative Radio and/or Chemotherapy in Patients With Rectal Cancer (ReSARCh)

Rectal Neoplasms

Italy
Fondazione IRCCS Istituto Nazionale dei Tumori,...
Istituto Oncologico di Bari

Completed

Dietary Intervention and BRCA Penetrance

Breast Cancer | BRCA1 Mutation | BRCA2 Mutation | Dietary Modification

Italy
Fondazione IRCCS Istituto Nazionale dei Tumori,...
University of Padova; Mount Sinai Hospital, Canada; Istituto Oncologico Veneto... and other collaborators

Recruiting

Desmoid Tumor and Pregnancy: Effect of Pregnancy on Disease Control and Effect of Diagnosis on Pregnancy History.

Pregnancy Complications | Pregnancy Loss | Desmoid | Desmoid; Abdominal

United States, Canada, France, Italy
University of Padova
Istituto Oncologico Veneto IRCCS; Azienda Ulss 2 Marca Trevigiana; Associazione... and other collaborators

Recruiting

IMMUNOlogical Microenvironment in REctal Adenocarcinoma Treatment (IMMUNOREACT1)

Rectal Cancer Stage T1-T2 | Rectal Cancer Nodal Metastasis

Italy
Regina Elena Cancer Institute
IRCCS Azienda Ospedaliero-Universitaria di Bologna; Fondazione IRCCS Istituto... and other collaborators

Recruiting

GENomic PROfilation for Therapeutic Purposes in SARComas and Molecular Tumor Board (MTB): Retrospective/Prospective Study in Referral Centers (PROGEN_SARC)

Sarcoma

Italy
Regina Elena Cancer Institute
University of Pisa; University of Roma La Sapienza; University of Turin, Italy; Istituto Oncologico Veneto IRCCS and other collaborators

Recruiting

Gender-based Impact on Safety and Efficacy of Lenvatinib in Patients With Differentiated Thyroid Cancer (Gisel)

Differentiated Thyroid Cancer | Gender

Italy
Fondazione IRCCS Istituto Nazionale dei Tumori,...
Federico II University; Humanitas Clinical and Research Center; Istituto Oncologico... and other collaborators

Recruiting

Targeting Triple Negative BREAst Cancer Metabolism With a Combination of Chemoimmunotherapy and a FASTing-like Approach in the Preoperative Setting: the BREAKFAST 2 Trial (BREAKFAST-2)

Breast Cancer | Triple Negative Breast Cancer | Fasting | Dietary Exposure

Italy
University of Padova
Azienda Ospedaliera di Padova; Istituto Oncologico Veneto IRCCS; Azienda Ulss... and other collaborators

Recruiting

IMMUNOlogical Microenvironment in REctal Adenocarcinoma Treatment. (IMMUNOREACT2)

Rectal Cancer

Italy
Fondazione IRCCS Istituto Nazionale dei Tumori,...
Istituto Di Ricerche Farmacologiche Mario Negri; Gruppo Oncologico del Nord-Ovest

Recruiting

Improving Outcome of Selected Patients With Non-resectable Hepatic Metastases From Colo-rectal Cancer With Liver Transplantation (COLT)

Neoplasms | Colorectal Cancer Metastatic | Liver Metastases | Liver Neoplasm

Italy
Regina Elena Cancer Institute
Centro di Riferimento Oncologico - Aviano; Fondazione Salvatore Maugeri; Istituti... and other collaborators

Recruiting

PRO Survivorship Concerns ITA (PRO)

Quality of Life | Psychological Distress | Breast Neoplasm Female

Italy

Clinical Trials Sponsored by Istituto Oncologico Veneto IRCCS

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Papua New Guinea

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations